Orchestra BioMed Holdings, Inc. presented key insights on its atrioventricular interval modulation (AVIM) therapy for managing high-risk hypertension at the CSI 2025 Meeting. The therapy aims to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results